Our weekly newsletter provides unparalleled data, insights and intelligence on the global psychedelics industry, straight to your inbox. Find the latest commercial deals, understand the latest regulatory changes and discover the most impactful scientific discoveries. Subscribe for free now.
Examining the business impact of North American psychedelic drug regulations; atai Life Sciences targets US$2.3 billion IPO valuation; and democrats introduce a bill to end the War on Drugs. Read more in Issue 33 of The Psychedelics Newsletter.
For-profit or non-profit? That is the ($100-billion) question. Rick Doblin and Christian Angermayer join the 7 July PSYCH Investor Summit: Research and Development to discuss the role of non and for-profit businesses in a can’t-miss conversation. Read more in Issue 31 of The Psychedelics Newsletter.
Dr. Carl Hart on the impediment of prolonged research; Field Trip appoints former US Senate Majority Leader as Special Adviser and Cybin studies sublingual psilocybin for major depressive disorder. Read more in Issue 30 of The Psychedelics Newsletter.
Announcing the next PSYCH Investor Summit: Research & Development, MindMed hits the NASDAQ and exploring the use of psychedelics to treat addiction. Read more in Issue 26 of The Psychedelics Newsletter.
Exploring the potential to create ethical psychedelics companies, a DNA test to inform psychedelic therapies, and preparing for the PSYCH Investor Summit: Europe and Asia. Read more in Issue 23 of The Psychedelics Newsletter.
The first-ever ketamine-assisted psychotherapy clinic has opened in the UK while Field Trip Health has confirmed the closing of $95m of funding. All this and more in Issue 20 of The Psychedelics Newsletter.
Following a breakout year for the psychedelic sector, the pharmaceutical industry is set to take on a more prominent role in the market in 2021 and beyond. Learn more and catch up with the latest investment trends and scientific findings in Issue 13 of The Psychedelics Newsletter.
The psychedelic compound known as DMT will be used in a trial to treat depression for the first time in the United Kingdom while MDMA has been proven to help people suffering from alcohol addiction. All this and more in issue 12 of the PSYCH Newsletter.
Gain access to every panel discussion from The PSYCH Symposium before time runs out and catch up on the latest news from across the international psychedelics industry in Issue 11 of The Psychedelics Newsletter, here.
A petition to legalise natural psychedelics in Canada reaches 13,000 signatures, and a Congressman has said psychedelics show promise in treating PTSD as Oakland activists also unveil guidelines for psychedelic healing ceremonies.
Canada approves end-of-life psilocybin treatment for palliative patients while UK scientists and experts propose easing restrictions for medical psychedelics and Californian activists propose easing restrictions for medical psychedelics.
An attempt to block the Washington D.C. psychedelic initiative fails, therapists request approval to test psychedelics in Canada and Oregon gets set to vote on psilocybin for therapeutic use in November 2020.
Oregon psilocybin decriminalisation campaign and DC activists say they will qualify for the November ballot while the New Medical Psychedelics Working Group to lobby for ease in UK research restrictions.
THE LATEST INSIGHTS, STRAIGHT TO YOUR INBOX
Join industry insiders and subscribe for exclusive news, data and insights from across the psychedelics industry.